Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
How do you approach worsening memory loss in patients with GCA?
Can it be directly related to disease activity or just a consequence of chronic inflammation?
Related Questions
How would you approach management of a young woman referred for isolated active anterior scleritis with a history of resolved right eye iritis, in the absence of systemic manifestations or end-organ involvement, but with serologies notable for strongly positive MPO and p-ANCA antibodies?
How would you approach management of a young woman referred for isolated anterior uveitis (now resolved), in the absence of systemic manifestations or end-organ involvement, but with serologies notable for strongly positive PR3 (negative c-ANCA)?
Can cryoglobulins be detected in patients with severe acrocyanosis in the absence of clinical evidence of active cryoglobulinemic vasculitis?
Would you consider switching to benralizumab for patients with EGPA experiencing severe pulmonary symptoms despite being on mepolizumab?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
Would you consider re-dosing rituximab in a patient with ANCA vasculitis (early glomerulonephritis, pulmonary nodules, sinus symptoms) who experiences a flare of the disease and return of CD19 cells 3 months after initial rituximab administration?
How do you approach requests for clearance for renal transplant in a patient with ANCA vasculitis who is on maintenance rituximab?
Do you continue PJP prophylaxis indefinitely in patients on rituximab maintenance therapy?
How do you approach treatment of livido vasculitis?
Can cryoglobulins be present in the setting of severe acrocyanosis without evidence of active cryoglobulinemic vasculitis?